Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 59-8862 in Aggressive Refractory Non-Hodgkin's Lymphoma
NCT00039156Phase 2Unknown
- Sponsor
- Theradex Oncology
- Start
- Jan 2002
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ortataxel in Non-Hodgkin lymphoma (NHL), sponsored by Theradex Oncology. Primary endpoint: Overall Tumor Response Rate. Status: unknown.
02
Drugs
ortataxel
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00039156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00039156.